Skip to main content
Premium Trial:

Request an Annual Quote

Stone Diagnostics to Provide Fibronostics Liver Disease Test

NEW YORK – Laboratory services provider Stone Diagnostics will offer Fibronostics' artificial intelligence-based liver disease test to physicians in the US, the companies announced on Tuesday. 

The Liverfast test uses artificial intelligence and 10 blood-based biomarkers to provide information about the degree of fibrosis, steatosis, and activity of a patient's liver, the companies said in a statement. 

The strategic partnership "gives us the comprehensive, efficient, reproducible, and scalable laboratory operations platform required to meet increasing Liverfast demand and allows us to focus on the most important needs of our prescribers and their patients," Brock Smith, Fibronostics general manager for the Americas, said in a statement. 

Financial and other terms of the deal were not disclosed.